Lakhesys SIGNED
Lakhesys: building the machine to make the medicines of tomorrow
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Lakhesys project word cloud
Explore the words cloud of the Lakhesys project. It provides you a very rough idea of what is the project "Lakhesys" about.
Project "Lakhesys" data sheet
The following table provides information about the project.
| Coordinator |
ASTRAVEUS SAS
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 2˙817˙143 € |
| EC max contribution | 1˙972˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-03-01 to 2021-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ASTRAVEUS SAS | FR (PARIS) | coordinator | 1˙972˙000.00 |
Map
Project objective
Chimeric Antigen Receptor T-cell therapies (‘CAR-T’) are ushering in an incredibly exciting era of using a patient’s own cells to cure their cancer. The prospect of using a patient’s own cells to cure their disease is theoretically limitless. However, with all of this excitement comes a shadow. The cost of these life-saving treatments is currently so prohibitive that it threatens to put extreme cost-pressure on healthcare providers globally in the years ahead.
Astraveus has developed a highly innovative microfluidic chip that can fundamentally change the CAR-T industry. This chip answers the need to lower production cost (by ~70%), improve treatment quality and allow upscaling of treatment volumes to the required levels. Astraveus has also developed equipment to optimize the use of these microfluidic chips. They have incorporated these technologies into a working prototype of an instrument called ‘Lakhesys’. This instrument allows for automated, standalone, end-to-end production of a CAR-T therapy.
The design, fabrication and validation of the microfluidic innovation is a real breakthrough in the ability to cheaply and accurately produce these treatments. The further step of incorporating these chips into a prototype system demonstrates the huge potential for automating CAR-T production. This phase-2 project will upgrade the supporting modules to turn this working prototype into a launch-ready product. It will also support the validation and industrialisation steps to bring this innovation to market.
The industry is dominated by players in the USA and China (72% of CAR-T institutions are based in these two countries). Astraveus has invented something incredibly unique and a complete step-change versus anything seen on the market. As such, we present an opportunity to support the creation of a homegrown EU business that can challenge the status quo and, more importantly, put these life-saving therapies in the hands of all patients who need them.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAKHESYS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LAKHESYS" are provided by the European Opendata Portal: CORDIS opendata.